Latest Breaking News On - Qing zhou - Page 1 : comparemela.com

Research Reveals New Lung Cancer Prognostic Biomarker: Chinese Journal

Research Reveals New Lung Cancer Prognostic Biomarker: Chinese Journal
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Qing zhouLibo tangRuiyang liHuahai wenChongrui xuFirst affiliated hospital of chongqing medical universitySouthern medical universityFirst affiliated hospitalChongqing medical universityChinese medical journal pulmonaryCritical care

Advancing Global Health Equity & Harmonization

Join us for the first annual Cure4Cancer conference focused on advancing global health equity and harmonization.

Qing zhouUnited statesJing qianNew south walesLong wuTerri conneranOrville schellLisag stuartGreg simonJohns hopkinsLillian leighIsabel mestresJohnv oylerOtis brawleyDebra eisenmanSebastian mondaca

ASCO 2023: Solid Tumors

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

United statesUniversity of chicagoNew havenNational taiwan universityT ai peiLong wuSan antonioSouth koreaAlpha biopharmaJie wangDennisj slamonDebra pattDennis slamonBorisa hadaschikRoys herbstRita nanda

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients immune system against cancer cells..

United statesHong kongQing zhouLong wuSan diegoAndrew zhuRichard yehGigi fengGuangdong academy of medical sciencesExchange commissionPrnewswire the company nasdaqGuangdong lung cancer instituteAmerican society of clinical oncologyClinical oncologyPrincipal investigatorGuangdong provincial people

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesQing zhouHong kongSan diegoMccormick placeGigi fengRichard yehExchange commissionMccormick place convention centerPrnewswire the company nasdaqAmerican society of clinical oncologyClinical oncologyAnnual meetingToripalimab combination therapyTrial results usingPotential predictive